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Background. Abdominal aortic aneurysm (AAA) is a focal aortic dilatation progressing
towards rupture. Non-invasive AAA-associated cell proliferation biomarkers are not yet
established. We investigated the feasibility of the cell proliferation radiotracer, fluorine-18-
fluorothymidine ([18F]FLT) with positron emission tomography/computed tomography (PET/
CT) in a progressive pre-clinical AAA model (angiotensin II, AngII infusion).
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Methods and Results. Fourteen-week-old apolipoprotein E-knockout (ApoE2/2) mice
received saline or AngII via osmotic mini-pumps for 14 (n = 7 and 5, respectively) or 28 (n = 3
and 4, respectively) days and underwent 90-minute dynamic [18F]FLT PET/CT. Organs were
harvested from independent cohorts for gamma counting, ultrasound scanning, and western
blotting. [18F]FLT uptake was significantly greater in 14- (n = 5) and 28-day (n = 3) AAA than
in saline control aortae (n = 5) (P < 0.001), which reduced between days 14 and 28. Whole-
organ gamma counting confirmed greater [18F]FLT uptake in 14-day AAA (n = 9) compared to
saline-infused aortae (n = 4) (P < 0.05), correlating positively with aortic volume (r = 0.71,
P < 0.01). Fourteen-day AAA tissue showed increased expression of thymidine kinase-1, equi-
librative nucleoside transporter (ENT)-1, ENT-2, concentrative nucleoside transporter (CNT)-
1, and CNT-3 than 28-day AAA and saline control tissues (n = 3 each) (all P < 0.001).
Conclusions. [18F]FLT uptake is increased during the active growth phase of the AAA
model compared to saline control mice and late-stage AAA. (J Nucl Cardiol 2019)
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Abbreviations
AAA Abdominal aortic aneurysm
USS Ultrasound scanning
PET Positron emission tomography
CT Computed tomography
[18F]FDG Fluorine-18 fluorodeoxyglucose
[18F]FLT Fluorine-18 fluorothymidine
ENT Equilibrative nucleoside transporter
CNT Concentrative nucleoside transporter
TK Thymidine kinase
ApoE-/- Apolipoprotein E-knockout
AngII Angiotensin II
ROI Region of interest
INTRODUCTION
Abdominal aortic aneurysm (AAA) is a focal
dilatation of the abdominal aorta that progresses to
rupture, which confers high mortality.1 AAA is detected
incidentally or through ultrasound scanning (USS)-
based screening programmes.2,3 Once detected, USS
monitoring is used to track AAA diameter until it
reaches the 5.5-cm intervention threshold; this can take
[ 10 years and places a discernible burden on
patients.4,5 A non-invasive stratification biomarker
applied at the time of AAA detection to personalize
monitoring regimens and identify those who may benefit
from a specific medical therapy or early intervention
would be beneficial. Positron emission tomography
(PET) can provide information about the molecular
processes beyond the anatomical characteristics of USS
or computed tomography (CT) and may therefore be
useful for this purpose.
Fluorine-18 fluorodeoxyglucose ([18F]FDG) is a
glucose uptake marker commonly used in oncology as
an indicator of high metabolic activity, such as at sites of
inflammation, and is the most commonly administered
PET radiotracer in clinical practice. The data on
[18F]FDG uptake in AAA are mixed and conflicting.6-9
Some studies suggest that increased [18F]FDG uptake
positively correlates with AAA progression,10-12, while
others indicate an inverse relationship or lack of
correlation between [18F]FDG uptake and aortic
size.13,14 The Sodium Fluoride Imaging of AAA
(SoFIA3) trial recently demonstrated that fluorine-18
sodium fluoride AAA uptake (reflecting microcalcifica-
tion) predicts AAA progression and rupture, providing
the first proof-of-concept data for PET/CT as a AAA
stratification biomarker 15; however, the mechanism
remains unclear.
Maegdefessel et al. showed that modulating micro-
RNA-21 expression reduces cell proliferation, protecting
mice from AAA expansion.16 Smooth muscle cell de-
differentiation and proliferation is an early event in
AAA.17 Preventing this event by deleting Kruppel-like
factor-4 prevents AAA formation in mice.18 These data
point to a period of pathological cellular remodeling in
early AAA and suggest that anti-proliferative therapy
might be beneficial. Therefore, detecting cell prolifera-
tion in vivo may be useful. Our hypothesis is that this
proliferative remodeling is detectable using PET/CT
with an analogue of the pyrimidine deoxynucleoside
thymidine, fluorine-18 fluorothymidine ([18F]FLT). This
tracer accumulates in proliferating cells and reflects
thymidine kinase-1 (TK-1) activity. Here, we investigate
[18F]FLT as a PET/CT radiotracer in the progressive
angiotensin II (AngII) infusion pre-clinical model of
AAA.
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METHODS
Animals
All animal work was conducted in accordance with
the UK Home Office, Animals (Scientific Procedures)
Act 1986 under Project Licence P606320FB. Male
JaxTM apolipoprotein E-knockout mice (ApoE-/-;
B6.129P2-Apoetm1Unc/J; Charles River, UK) were
used for experiments at 14 weeks of age. Male
C57BL6/J mice (Charles River, UK) were used at 8
weeks of age for baseline biodistribution studies. All
animals were part of the Jackson Laboratories Genetic
Stability Programme to limit cumulative genetic drift.
Mice were maintained at 21 C with a 12-hour light/-
dark cycle and 50% to 70% humidity in GM500
individually ventilated cages (Techniplast, Italy) and
fed standard chow diet and Hydropac water ad libitum.
All mice were provided with a housing dome and two
chew sticks as environmental enrichment.
For the AngII AAA model, 14-week-old male
ApoE-/- mice (Jackson Laboratories) received human
AngII (Sigma A9525) infusions at 750 ngkg-1min-1
via Alzet 1002 (14 days) or 1004 (28 days) osmotic
mini-pumps that were implanted subcutaneously by
posterior neck incision under recovery isoflurane anaes-
thesia, as described previously.19 ApoE-/- controls
received saline infusions via identical pumps.
[18F]FLT Production
[18F]FLT was prepared from fluorine-18 fluoride
produced using an on-site 7.5-MeV ABT Biomarker
Generator cyclotron and purified using an in-house-
developed microfluidic electrochemical cell for elec-
trode trapping, through which irradiated target water
(0.5 mL, oxygen-18 H2O) containing ca. 1 GBq (27.03
mCi) of fluorine-18 fluoride was pumped at 0.2
mLmin-1 while applying a 20 V potential, and the cell
was flushed with 2 mL of MeCN at 1 mLmin-1 with no
potential applied. Subsequently, 0.4 mL of a solution
containing KHCO3 (30 mM) and K222 (37 mM) in
MeCN was pumped through the cell at 40C at 0.1
mLmin-1. Ten mg of fluorothymidine precursor 30-N-
Boc-50-dimethoxytrityl-30-O-nosyl-thymidine was added
to the released solution to perform a radio-labeling
reaction at 100 C for 10 minutes. After the fluorination,
the unreacted fluorine-18 fluoride was trapped on the
neutral alumina cartridge (light) and reaction mixture
treated for 5 minutes at room temperature with an
equivalent volume of 2 N HCl solution. The mixture was
then neutralized with a stoichiometric amount of 8 N
NaOH solution and purified by semi-preparative high-
performance liquid chromatography on an ACE 5 C18
10 9 250 5A column eluted with 35% acetonitrile in
water (both 0.1% trifluoroacetic acid) (flow rate= 4.7
mLmin-1, Rt= 12 minutes). The high-performance
liquid chromatography fraction containing partially
protected product was diluted two to three-fold with
water and passed over an HBL Oasis C18 cartridge.
Trapped product was eluted with 0.5 mL of ethanol and
3 mL of diethyl ether and dried at 60 C under an inert
gas stream. The heat applied for drying generated the
fully deprotected [18F]FLT (confirmed by analytical
high-performance liquid chromatography with a cold
fluorine-19 FLT standard), which was re-dissolved in
10% ethanol/phosphate-buffered saline solution, filtered
through a 0.22-lm filter for sterility, and delivered for
animal administration. Tracer preparation started with
1.0 to 1.3 GBq (27.03 to 35.14 mCi) of cyclotron-
produced fluorine-18 fluoride and yielded 40 ± 8 MBq
(1.08 ± 0.22 mCi) (n.d.c.) [18F]FLT intravenous-in-
jectable formulation in 136 ± 15 minutes (n = 5)
(RCY (decay-corrected)= 8% ± 2%).
In Vivo PET/CT
Mice were induced with 5% isoflurane/oxygen (v/v)
anaesthesia before maintenance at 2% at 1 Lmin-1.
Mice were cannulated in the tail vein using a bespoke
catheter before being placed into an imaging cell where
temperature and respiration were monitored (Minerve,
France). [18F]FLT was injected with the following
means ± standard deviations (SDs) of activity in 200
lL of 0.9% saline solution (Aqupharm No1, Animalcare
Ltd., York, UK) through the pre-cannulated lateral tail
vein at the beginning of a 90-minute dynamic imaging
sequence: 7.27 ± 2.89 MBq (0.20 ± 0.08 mCi) (14-day
scans; n = 12) and 10.08 ± 1.77 MBq (0.27 ± 0.05
mCi) (28-day scans; n = 7). Images were acquired using
the Super Argus (Sedecal) small-animal PET/CT scan-
ner, with animals placed prone and the field-of-view
centered on the abdominal aorta. Mice were maintained
at 1% anaesthesia during scanning, with temperature and
respiration monitored throughout. Following the PET
scan, a CT image was acquired for anatomic co-
registration (40 kV, 140 lA, 360 projections, 8 shots).
PET images were histogrammed into 15 2-seconds, 2
15-seconds, 4 60-seconds, 1 300-seconds, and 8 600-
seconds frames and reconstructed using the three-
dimensional ordered subsets expectation maximization
algorithm with 2 iterations and 16 subsets with atten-
uation correction, yielding voxel dimensions of
0.39 9 0.39 9 0.78 mm3.
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PET/CT Image Analysis
Animals with failed or paravenous radiotracer
injection (2/5 in the saline control group, 2/5 in the
14-day AngII AAA group, and 1/4 in the 28-day AngII
AAA group) were excluded from the analysis. Three-
dimensional isocontour regions of interest (ROIs) incor-
porating the supra-renal abdominal aortic area (between
the renal arteries and diaphragm) were manually drawn
on the reconstructed images using AMIDE v1.0.4
software. The aortic ROI was constructed between the
kidneys and anterior to the anterior border of the
vertebral column based on the CT images including the
most prominent PET signal in the 80 to 90-minute
timeframe. For saline controls, the aortic ROI was
constructed between the kidneys, superior to the bladder,
and anterior to the anterior border of the vertebral
column based on the CT images. These ROIs had
dimensions of 1.08 mm3 and contained 15 voxels (see
Supplementary Figure 1 for example visual representa-
tion of ROIs). Incorporating mouse weights and injected
radioactivity doses, the output statistics revealed the
maximum and mean standardized uptake values (SUVs-
) across all frames. These values were used to generate
time-activity curves for ROIs in the abdominal aorta (as
shown in Supplementary Figure 2), spleen, kidneys, and
urinary bladder. The maximum SUV (SUVmax) was
chosen as the metric of choice to quantify the aortic ROI
to avoid partial volume effects of the adjacent kidneys
and bladder, where high [18F]FLT signals were observed
consistently.
Histological Staining
Murine aortae were fixed in situ by perfuse fixation
with 10 mL of phosphate-buffered saline followed by 5
mL of 4% paraformaldehyde in terminally anaesthetized
animals and then fixed at 4 C for 48 hours before they
were embedded in Cellwax (Cellpath Ltd., UK) using a
Leica EG1150H embedding station. Four-lm thickness
sections were cut onto Plus Frost slides (Solmedia, UK)
using a Leica RM2235 microtome. Proliferating cells
were stained with rabbit anti-mouse Ki67 antibody
(ab15580, Abcam; 1:750 dilution) for 1 hour and
Menapath Polymer HRP secondary antibody (Menarini
Diagnostics Ltd., Winnersh, UK) for 30 minutes. Slides
were counterstained with haematoxylin and imaged
using the Aperio AT2 (Leica Biosystems, Wetzlar,
Germany) digital pathology slide scanner with 9 20
maximal magnification. All quantitative analyses were
performed using ImageJ 1.51k software.20 For quantifi-
cation of the Ki67 staining, the proportion of Ki67-
positive nuclei was determined in three 50-lm2 ROIs
and averaged for each animal.
Protein Quantification
An independent cohort of animals was used to
harvest tissue at baseline and after 28-day saline, 14-day
AngII, and 28-day AngII infusions. Aortic tissue (supra-
renal abdominal aortic segment only) was harvested
under terminal isoflurane anaesthesia, snap-frozen in
liquid nitrogen after phosphate-buffered saline perfu-
sion, and stored at - 80 C until use. Proteins were
extracted using cell extraction buffer (FNN0011, Invit-
rogen) supplemented with Protease Inhibitor Cocktail
(P8340, Sigma). The DC Protein assay kit (5000112,
Bio-Rad) was used to quantify isolated proteins. The
average yield was more than 3 mg of protein per aorta.
Western blotting was performed for TK-1, a key enzyme
expressed during DNA synthesis and the substrate for
[18F]FLT, and the specific carriers responsible for the
transport of both [18F]FLT and thymidine across the cell
membrane: equilibrative nucleoside transporter (ENT)-1
and -2 and concentrative nucleoside transporter (CNT)-1
and -3. For each protein, blots were conducted as per the
manufacturer’s suggestions using 100 lg of protein per
well. Antibodies and dilutions used were anti-TK-1,
1:500 (GTX113281; GeneTex, CA, USA); ENT-1,
1:1000 (ab135756); ENT-2, 1:1000 (ab181192); CNT-
1, 1:500 (ab192438); CNT-3, 1:500 (ab223085); and b-
actin, 1:1000 (Ab8226; all Abcam, Cambridge, UK).
Proteins were detected using SuperSignal West Femto
Maximum Sensitivity enhanced chemiluminescent sub-
strate (ThermoFisher Scientific, Loughborough, UK).
ImageJ 1.51k software was used to quantify the optical
intensity of the bands relative to that of corresponding b-
actin bands.20
In Vivo USS
USS was performed under 5% recovery isoflurane
anaesthesia before maintenance at 2% using the
Vevo2100 high-resolution (30 lm), high-frequency
pre-clinical lUSS system (Visualsonics, FUJIFILM
VisualSonics, Inc., Toronto, ON, Canada) with an MS-
550D transducer at a 40-MHz frequency on a heated
platform maintaining a core body temperature of 35 to
37 C. Prior to imaging, the abdomen area was shaved
and hair removed using depilatory cream. Imaging was
performed using Aquasonic clear gel (Parker Labs).
Transverse imaging was acquired with a motor along an
11.96-mm ROI from the right renal artery in a cranial
direction with 157 frames at 0.076-mm intervals gated
for respiration with electrocardiographic triggering 50
ms after the r-wave. Images were reconstructed and
measured using Vevo Lab v1.7.0 (VisualSonics, FUJI-
FILM VisualSonics, Inc., Toronto, ON, Canada) to
generate three-dimensional lumen volume
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measurements. For the co-registration analysis, bony
landmarks on CT and USS were aligned and displayed
using ImageJ 1.51k.
Ex Vivo Gamma Counting
Animals were anaesthetised with 5% isoflurane with
an oxygen flow rate of 2 Lmin-1. [18F]FLT in 100 lL
of 0.9% saline solution (Aqupharm No1, Animalcare
Ltd., York, UK) was injected into the tail vein at the
following doses (mean ± SD): C57BL6/J study,
6.07 ± 2.57 MBq (0.16 ± 0.07 mCi); AngII AAA study,
0.25 ± 0.32 MBq (0.01 ± 0.01 mCi). For the AngII
AAA ex vivo gamma counting study, we reduced the
injected dose to allow more animals to be included in a
single experiment with a single delivery of [18F]FLT.
This was possible due to the high sensitivity of the
Hidex gamma counter. Animals were recovered for 90
minutes and subsequently humanely culled by cervical
dislocation under Schedule 1 of the UK (Scientific
Procedures) Act 1986. Samples (blood, plasma, heart,
spleen, kidneys, small and large intestines, supra-renal
abdominal aorta, bone, and tail) were collected,
weighed, and measured for radioactivity using a gamma
counter (Hidex). Importantly, blood was removed from
the aortic lumen before it was placed in the gamma
counter. All ex vivo biodistribution data were decay-
corrected, and radioactivity counts were expressed as the
percentage of injected dose per gram of tissue (%ID/g).
Ex Vivo Autoradiography
Following a 90-minute delay for biodistribution and
gamma counting, spleen, control aorta, and 14-day
AngII AAA whole-organ samples were placed on a
phosphor screen (PerkinElmer) covered with clear
cellophane wrap. After overnight exposure, the imaging
plates were scanned using the Cyclone Plus imager
(PerkinElmer) at a resolution of 300 DPI. Images were
processed using OptiQuant software (PerkinElmer).
Statistical Analysis
All statistical analyses were performed using Origin
2017 software (OriginLab Corporation, Northampton,
MA, USA). All graphs show the mean ± the standard
error of the mean (SE) unless otherwise stated. Histol-
ogy, USS, and some gamma counting results were
analyzed using two-sampled t tests with Welch’s cor-
rection. PET/CT, western blotting, and some gamma
counting results were analyzed using one-way analysis
of variance with post hoc Bonferroni-Holm correction.
The threshold for statistical significance was set at
P\ 0.05.
RESULTS
Cell Proliferation Occurs in AngII AAA
As expected, ApoE-/- mice infused with AngII
developed significant supra-renal aortic lumen dilatation
compared to the saline-infused controls (Figure 1A). To
test for cell proliferation in AngII AAA, we stained fixed
supra-renal abdominal aortic tissue from ApoE-/- mice
infused with saline or AngII for 28 days with Ki67,
which accumulates in cells throughout the S, G2, and M
cell cycle phases.21 A significant increase in the pro-
portion of Ki67-positive nuclei was observed in the
aortic wall in AngII-infused mice compared to saline
controls (P\ 0.001, Figure 1B to C), and this was
positively correlated with aortic volume (Figure 1D).
[18F]FLT Uptake and TK-1 Expression are
Increased in AngII AAA
Twenty-two mice were enrolled in the PET/CT
study: five in the saline control group and seventeen in
the AngII infusion group. Within the first 14 days of the
study, ten mice died from aortic rupture in the AngII-
infused group (8 thoracic, 2 abdominal), leaving twelve
mice (5 saline controls and 7 AngII-infused) for imag-
ing. A further four mice (2 saline controls and 2 AngII-
infused) were excluded due to paravenous radiotracer
injection. The PET/CT images obtained from the
remaining 8 animals (3 saline controls and 5 AngII-
infused) suggested increased [18F]FLT uptake in abdom-
inal aortic ROIs (as shown in Supplementary Figure 1)
after 14- and 28-day AngII infusions compared to saline
controls. Notably, the signal was more intense after 14
days of AngII infusion, corresponding to the active
growth phase in the AngII AAA model, than that after
28 days, corresponding to the end of the growth phase
(Figure 2A; Supplementary Figure 3A to C, Supple-
mentary Videos 1 to 4). It is noteworthy that repeat
imaging of the AngII-infused mice on day 28 was
limited to 3 animals as 1 injection was paravenous and 1
animal died from aortic rupture at the time of radiotracer
injection. Splenic [18F]FLT uptake was observed con-
sistently. Uptake was observed in the kidneys from 0.5
to 90 minutes and urinary bladder from 2 to 90 minutes
after scan initiation, per its predominant renal clearance.
For quantification, SUVmax and mean SUVs (SUV-
mean) were used to construct time-activity curves for 0 to
90-minute aortic uptake post-[18F]FLT administration.
Uptake in the saline control aortic ROIs remained
consistently low throughout each scan. Meanwhile, all
time-activity curves of the AngII AAA ROIs exhibited
an initial peak corresponding to the bolus injection in the
vena cava, followed by a plateau and late peak in the
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final 10 minutes of the scan (Supplementary Figure 2,
Video 2). All subsequent SUV analyses were based on
tracer uptake in the 80 to 90-minute timeframe.
Quantification and statistical analysis in all manu-
ally drawn ROIs revealed the following maximum SUVs
(mean ± standard error of the mean): 0.007 ± 0.002,
saline control; 0.31 ± 0.03, 14-day AngII AAA;
0.20 ± 0.05, 28-day AngII AAA. Significantly greater
[18F]FLT uptake was observed in 14-day (P\ 0.001)
and 28-day (P\ 0.001) AngII AAA compared to saline
controls. The signal significantly decreased between 14-
and 28-day AngII AAA (P\ 0.01) (Figure 2B). Similar
results were observed for SUVmean (Figure 2B).
When USS was performed just before [18F]FLT
PET/CT and the images were co-registered using bony
landmarks, the observed PET signal appeared to overlay
the remodeled and thickened aortic wall at the site of the
aneurysm (Figure 2C).
Next, using an independent cohort of mice, we
harvested the aortae at baseline and after saline and 14-
and 28-day AngII infusions. We then extracted protein
and performed western blotting for TK-1, the [18F]FLT
substrate. We observed significantly increased TK-1
expression following 14-day AngII infusion compared
to controls (P\ 0.001) and significantly decreased TK-
1 expression between 14- and 28-day AngII infusions
(P\ 0.001) (Figure 2D; uncropped blots in Supplemen-
tary Figure 4A), in keeping with the pattern of [18F]FLT
activity observed during the PET/CT experiments.
To further confirm that the [18F]FLT PET/CT signal
was reflective of proliferation, we treated AngII AAA
mice with vehicle or the anti-proliferative agent imatinib
Figure 1. Ki67 is upregulated in 28-day AngII AAA tissue and correlated with aortic volume. (A)
Aortic volumes in 28-day AngII AAA (n = 6) vs saline control aortae (n = 3). **P\ 0.01 on two-
sampled t test with Welch’s correction. (B) Immunohistochemical 3,30-diaminobenzidine staining
for Ki67 in AngII AAA (n = 6) and saline control (n = 3) aortae. Positive staining is brown. (C)
Quantitative analysis of images in (B), % of Ki67-positive nuclei. ***P\ 0.001 on two-sampled t
test with Welch’s correction. (D) Correlation between aortic volume and Ki67-positive nuclei.
Pearson’s r = 0.81; black, saline control; blue, AngII AAA. AngII AAA, angiotensin II abdominal
aortic aneurysm.
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by oral gavage for 3 days after the initial PET/CT scan
and then repeated the imaging. The signal in the aortic
ROI diminished after imatinib treatment but was
unchanged following vehicle treatment (Supplementary
Figure 5).
Key [18F]FLT Transporter Proteins are
Upregulated in AngII AAA
Many [18F]FLT transporters are upregulated in
cancer, aiding efficient [18F]FLT accumulation in pro-
liferative cells.22,23 We observed significantly increased
ENT-1, ENT-2, CNT-1, and CNT-3 expression in 14-
day AngII AAA than in saline control aortae (P\ 0.001
for all) and in 28-day AngII AAA (P\ 0.001 for all).
Any differences between baseline and saline control
aortae were insignificant (Figure 3A to D; full uncrop-
ped blots in Supplementary Figure 4B to E).
Aortic [18F]FLT Uptake is Correlated
with Aortic Lumen Volume
As expected, baseline [18F]FLT biodistribution
revealed high splenic uptake and low aortic and heart
uptake. The aorta exhibited comparable uptake to the
heart, while the spleen exhibited greater uptake relative
to the heart (P = 0.69 vs P\ 0.001) (Figure 4A); we
therefore used the heart and spleen as negative and
positive control tissues, respectively, for the AngII AAA
study.
Three-dimensional USS demonstrated the expected
aortic lumen volume increase following 14-day AngII
infusion compared to saline-infused controls
(15.34 ± 0.80 mm3 vs 11.16 ± 0.73 mm3, P\ 0.01,
Figure 4B). To confirm the origin of the aortic [18F]FLT
signal, we performed ex vivo gamma counting of the
aorta and spleen normalized to the heart following PET/
Figure 2. [18F]FLT uptake and TK-1 expression are greater in the 14-day AngII AAA model. (A)
Representative coronal-view static [18F]FLT PET/CT images 80 to 90 minutes post-[18F]FLT
injection. White arrows indicate abdominal aortic location (short arrow, saline control; long arrow,
AAA). (B) Maximum and mean SUV analyses of abdominal aortic regions of interest on images in
(A) of saline controls (n = 5), 14-day AngII AAA (n = 5), and 28-day AngII AAA (n = 3). (C)
Representative transverse-view [18F]FLT PET/CT, ultrasound, and fused ultrasound-PET/CT
images (short arrow, aortic lumen; long arrow, remodeling aortic wall). (D) Representative TK-1
and b-actin western blots and quantitative analysis, optical intensity of TK-1 band/optical intensity
of b-actin band for baseline aortae (n = 3), saline control (n = 3), 14-day AngII AAA (n = 3), and
28-day AngII AAA (n = 3). ***P\ 0.001, **P\ 0.01, ns, not significant on one-way analysis of
variance with post hoc Bonferroni-Holm correction. [18F]FLT, [18F]fluorothymidine; AngII,
angiotensin II; AAA, abdominal aortic aneurysm; PET/CT, positron emission tomography/computed
tomography; SUV, standardized uptake value; TK-1, thymidine kinase-1.
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CT (to control for mouse-to-mouse variability). We
observed significantly increased [18F]FLT counts in
aortic tissue from 14-day AngII-infused mice compared
to saline controls (relative to the heart: P\ 0.05,
Figure 4C), consistent with our PET/CT and TK-1
western blotting data. The counts in 14-day AngII AAA
were comparable to those observed in the spleen (%ID/g
relative to the heart, mean ± standard error of the mean):
2.09 ± 0.32 and 2.19 ± 0.21, respectively. Ex vivo
autoradiography further supported these data (Fig-
ure 4C). We observed a significant positive correlation
between aortic volume and [18F]FLT uptake by gamma
counting (Pearson’s r = 0.71, P\ 0.01) (Figure 4D).
The in vivo PET signal was also positively correlated
with the ex vivo gamma counting signal when per-
formed in the same animals (Figure 4E).
DISCUSSION
This is the first study to explore the feasibility of
[18F]FLT PET/CT in an experimental murine model of
progressive AAA. We demonstrated that [18F]FLT
uptake in AngII-induced AAA increased after 14 days
of infusion compared to saline controls with subsequent
signal fall-off after 28 days. This was corroborated by a
similar pattern of TK-1 protein expression in an inde-
pendent cohort of animals. We confirmed that the
[18F]FLT signal was originating from the aortic tissue by
performing ex vivo gamma counting of supra-renal
aortic tissue (without blood) and co-registered the PET/
CT and USS data. Furthermore, ENT-1, ENT-2, CNT-1,
and CNT-3 levels were observed to have increased in
AngII AAA.
Initially, both [18F]FLT and thymidine are trans-
ported across the cell membrane via passive diffusion or
specific carriers (ENT-1/2, CNT-1/3). The fluorine atom
replacing the 3’ hydroxyl group prevents [18F]FLT from
incorporating into DNA and proceeding along the
thymidine mechanistic pathway. The cytosolic accumu-
lation of phosphorylated [18F]FLT is detected using
PET, reflecting TK-1 activity and thus proliferation.24,25
Phosphorylated [18F]FLT is unable to escape from cells
and acts selectively as a substrate for TK-1, but not TK-
2, contributing to the tracer’s specificity.26
[18F]FLT has been identified as a suitable PET
radiotracer to assess proliferative activity in
tumors.24,27,28 More recently, Ye et al. demonstrated
[18F]FLT PET/CT uptake in atherosclerosis and a weak
association between [18F]FLT and [18F]FDG uptake,
suggesting that glucose metabolism and cell prolifera-
tion may be weakly associated in this context.29 Our
results support the idea that [18F]FLT uptake might be
useful in AAA as opposed to [18F]FDG uptake, for
which the existing data are conflicting.
Selective [18F]FLT phosphorylation, and thus its
uptake and retention in the cytosol, is limited by TK-1
Figure 3. ENT-1, ENT-2, CNT-1, and CNT-3 expression is upregulated in 14-day AngII AAA
tissue. Western blots for ENT-1 (A), ENT-2 (B), CNT-1 (C), and CNT-3 (D). All blots were
repeated thrice in tissues from independent animals. The protein of interest was normalized to b-
actin. ***P\ 0.001, ns, not significant on one-way analysis of variance with post hoc Bonferroni-
Holm correction. [18F]FLT, [18F]fluorothymidine; ENT, equilibrative nucleoside transporter; CNT,
concentrative nucleoside transporter; AngII AAA, angiotensin II abdominal aortic aneurysm.
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during cell synthesis.30 It is therefore important that we
observed significantly increased TK-1 expression after
14-day AngII infusion, when we observed the greatest
[18F]FLT uptake on PET. TK-1 overexpression is
similarly observed in cancer models,30,31 and its asso-
ciation with the Ki67 proliferation index has been
demonstrated in various cancers.32-34 Interestingly,
AAA [18F]FLT uptake was observed after 14 days of
AngII infusion, when aneurysms expand, but this effect
was weaker after 28 days, when the growth phase begins
to plateau, suggesting decreased cell proliferation in
late-stage AAA. This supports the idea of early-stage
cellular remodeling leading to late-stage replicative
senescence, which has been reported in end-stage human
AAA samples.17,35,36 The early proliferative period may
drive disease progression, but this theory requires further
pre-clinical and clinical evaluation.
The nucleoside transporters that transport [18F]FLT
into cells may also influence [18F]FLT uptake: ENT-1,
ENT-2, CNT-1, and CNT-3. Paproski et al. character-
ized [18F]FLT transport by these transporters in cancer
cells and demonstrated that they—particularly ENT-1 in
murine tumor models—facilitate [18F]FLT uptake.22,23
Consistent with increased 14-day AngII AAA [18F]FLT
uptake on in vivo PET/CT and ex vivo gamma counting,
these transporters were significantly upregulated in 14-
day AngII AAA tissues. The established association
between [18F]FLT uptake and thymidine-associated
marker expression in cancer is interesting to draw
parallels with that in AAA. While concomitant malig-
nancies occur in up to 14% of AAA cases 37 and
smoking is an important shared risk factor between the
two pathologies, we do not suggest a shared mechanism
to the proliferation observed in our study in AAA and
Figure 4. Aortic volume and [18F]FLT uptake are positively correlated. (A) Decay-corrected
ex vivo [18F]FLT counts per mass units in baseline control C57BL6 mice (n = 4). Comparisons are
shown for positive (spleen) vs negative (heart) controls and tissue of interest (aorta) vs heart.
***P\ 0.001, ns, not significant on one-way analysis of variance with post hoc Bonferroni-Holm
correction. (B) Representative USS three-dimensional aortic lumen reconstructions and volumes in
14-day AngII AAA (n = 9) vs saline control aortae (n = 4). **P\ 0.01 on two-sampled t test with
Welch’s correction. (C) Decay-corrected ex vivo [18F]FLT counts per mass units in spleens and
abdominal aortae relative to the hearts from AngII AAA (n = 3) and saline control (n = 3) mice,
and example ex vivo [18F]FLT autoradiography image using the same tissues. *P\ 0.05 on two-
sampled t test with Welch’s correction. The spleen is included as reference. (D) Correlation
between aortic volume and ex vivo [18F]FLT counts per mass units. Pearson’s r = 0.71, P\ 0.01.
(E) Correlation between SUVmax and ex vivo [
18F]FLT counts per mass units. Pearson’s r = 0.86;
black, saline control; blue, AngII AAA. USS, ultrasound scanning; AngII AAA, angiotensin II
abdominal aortic aneurysm; [18F]FLT, [18F]fluorothymidine; SI/LI, small and large intestines;
SUVmax, maximum standardized uptake value.
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that previously reported in cancer. We merely observe
that both pathologies involve cell proliferation.
Some limitations are associated with our study. The
AngII AAA mouse model exhibits a high rate of
mortality due to aneurysm rupture.38 Importantly, rup-
ture in this model is not typically due to AAA
progression, but is an early event in AAA initiation.
Regarding PET/CT image analysis, the abdominal aorta
and spleen are both anatomically near the bladder and
kidneys, which readily take up [18F]FLT during excre-
tion and consequently raise the possibility of signal
spill-over into the aortic ROI. The ability to definitively
study the aortic wall was also limited by the PET
scanner’s spatial resolution (1 mm), making it difficult
to evaluate tracer uptake in aneurysmal regions. To
mitigate this risk, we used SUVmax for PET/CT analysis
so that partial volume effects were minimal. We also
took efforts to confirm that the PET/CT signal was
originating from the aortic wall by conducting ex vivo
gamma counting and performing co-registration of the
3D USS and PET datasets. Finally, the cell type(s)
contributing to this proliferative [18F]FLT signal are
insufficiently clear from our study, warranting further
investigation.
NEW KNOWLEDGE GAINED
In 14-day AngII-induced AAA compared to 28-day
AngII-induced AAA and saline controls, the [18F]FLT
PET signal is significantly enhanced and [18F]FLT
counts are greater, which themselves correlate with
aortic volume. The expression of the [18F]FLT substrate,
TK-1, and [18F]FLT transporter proteins ENT-1, ENT-2,
CNT-1, and CNT-3 are also increased in AngII AAA.
These findings suggest an early period of cell prolifer-
ation in the AngII AAA murine model, which is
detectable using PET/CT.
CONCLUSIONS
[18F]FLT is increased during the active growth
phase of the AngII AAA murine model compared to
saline control animals or late-stage AngII AAA.
[18F]FLT uptake is correlated with aortic volume. The
expression of the [18F]FLT substrate TK-1 is also
increased in the model. Further work is necessary to
determine the cell types contributing to the proliferative
signal.
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